Identification and analysis of an early diagnostic marker for malignant melanoma: ZAR1 intra-genic differential methylation.

Journal of Dermatological Science
Yui ShinojimaHiroki Nagase

Abstract

Epigenetic changes such as aberrant DNA methylation and histone modification have been shown to play an important role in the tumorigenesis of malignant melanoma. To identify novel tumor-specific differentially methylated regions (DMRs) in human malignant melanoma. The aberrant methylation at 14 candidate human genomic regions identified through a mouse model study with quantitative DNA methylation analysis using the Sequenom MassARRAY system was performed. The CpG island Exon 1 region of the Zygote arrest 1 (ZAR1) gene, which is responsible for oocyte-to-embryo transition, showed frequent aberrant methylation of 28 out of 30 (93%) melanoma surgical specimens, 16 of 17 (94%) melanoma cell lines, 0% of 4 normal human epidermal melanocyte (NHEM) cell lines, 0% of 10 melanocytic nevi and 100% of 51 various cancer cell lines. According to the real-time RT-PCR, the ZAR1 gene was overexpressed in part of the hypermethylated cell lines, while its low expression with bivalent histone methylation status was seen in unmethylated cell lines. Our findings suggest that the ZAR1 intra-genic differentially methylated region would be a useful tumor marker for malignant melanoma and may be other type of cancers. The involvement of ZAR1 in the c...Continue Reading

References

Jun 22, 2000·International Journal of Cancer. Journal International Du Cancer·C E SalemG Liang
May 30, 2003·Biology of Reproduction·Xuemei WuMartin M Matzuk
Sep 2, 2005·Nature Reviews. Genetics·Keith D Robertson
Oct 13, 2005·Molecular and Cellular Endocrinology·Holly A LaVoie
Oct 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Mathias EhrichDirk van den Boom
Aug 17, 2006·Genes & Development·Lynda ChinDavid E Fisher
Mar 21, 2007·Pigment Cell Research·Tanja Rothhammer, Anja-Katrin Bosserhoff
Oct 30, 2007·Epigenetics : Official Journal of the DNA Methylation Society·Joseph F SmithWilliam A Held

❮ Previous
Next ❯

Citations

Feb 19, 2011·Brain Tumor Pathology·Takao WatanabeHiroki Nagase
Jan 6, 2011·Neurologia Medico-chirurgica·Takao WatanabeHiroki Nagase
Jun 19, 2012·Clinical Epigenetics·Norishige YamadaSuguru Yonezawa
Jun 19, 2013·Wiley Interdisciplinary Reviews. RNA·Amanda CharlesworthCornelia H de Moor
May 3, 2014·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Priscilla BrebiJuan C Roa
Apr 16, 2013·Journal of Pediatric Surgery·Kiminobu SugitoHiroki Nagase
Jan 29, 2017·Protein Engineering, Design & Selection : PEDS·Jonathan M Cook, Amanda Charlesworth
Dec 6, 2019·Clinical Epigenetics·Verena DeutschmeyerAntje M Richter
Jun 8, 2017·Clinical Epigenetics·Antje M RichterReinhard H Dammann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.